Species differences in ciprofloxacin resistance among Gram-negative bacteria: can “anti-mutant” ratios of the area under the concentration–time curve to the MIC be achieved clinically?

References

• Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011;9:894–896.10.1038/nrmicro2693
   PubMed Web of Science ®Google Scholar
• Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013;66:571–591.10.1038/ja.2013.86
   PubMed Web of Science ®Google Scholar
• Lister P. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochem Pharmacol. 2006;71:1057–1065.10.1016/j.bcp.2005.10.038
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015;36:136–153.10.1055/s-00000075
   PubMed Web of Science ®Google Scholar
• Firsov AA, Zinner SH, Lubenko IY. In vitro dynamic models as tools to predict antibiotic pharmacodynamics. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T, editors. Antimicrobial pharmacodynamics in theory and clinical practice. 2nd ed. New York: Informa Healthcare USA; 2007. p. 45–78.10.3109/indt
   Google Scholar
• Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1604–1613.10.1128/AAC.47.5.1604-1613.2003
   PubMed Web of Science ®Google Scholar
• Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004;54:178–186.10.1093/jac/dkh242
   PubMed Web of Science ®Google Scholar
• Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents. 2008;32:488–493.10.1016/j.ijantimicag.2008.06.031
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of Moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 2003;47:1088–1095.10.1128/AAC.47.3.1088-1095.2003
   PubMed Web of Science ®Google Scholar
• Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003;52:616–622.10.1093/jac/dkg401
   PubMed Web of Science ®Google Scholar
• Oonishi Y, Mitsuyama J, Yamaguchi K. Effect of GrlA mutation on the development quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. J Antimicrob Chemother. 2007;60:1030–1037.10.1093/jac/dkm344
   PubMed Web of Science ®Google Scholar
• Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counter select resistance. Antimicrob Agents Chemother. 2007;51:744–747.10.1128/AAC.00334-06
   PubMed Web of Science ®Google Scholar
• Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:2409–2412.10.1128/AAC.00975-10
   PubMed Web of Science ®Google Scholar
• Linder KE, Nicolau DP, Nailor MD. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I Gram positive bacteria. Expert Opin Drug Metab Toxicol. 2016;12:267–280.10.1517/17425255.2016.1141197
   PubMed Web of Science ®Google Scholar
• Firsov AA, Strukova EN, Shlykova DS, Portnoy YA, Kozyreva VK, Edelstein MV, et al. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013;57:4956–4962.10.1128/AAC.00578-13
   PubMed Web of Science ®Google Scholar
• Firsov AA, Portnoy YA, Strukova EN, Shlykova DS, Zinner SH. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents. 2014;44:301–305.10.1016/j.ijantimicag.2014.06.013
   PubMed Web of Science ®Google Scholar
• Firsov AA, Strukova EN, Portnoy YA, Shlykova DS, Zinner SH. Bacterial antibiotic resistance studies using in vitro dynamic models: population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015;46:313–318.10.1016/j.ijantimicag.2015.06.007
   PubMed Web of Science ®Google Scholar
• Gebru E, Choi M-J, Lee S-J, Damte D, Park SC. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin. J Med Microbiol. 2011;60:1512–1522.10.1099/jmm.0.028654-0
   PubMed Web of Science ®Google Scholar
• Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, Zinner SH, Firsov AA. Searching for the optimal predictor for ciprofloxacin resistance in Klebsiella pneumoniae by using in vitro dynamic models. Antimicrob Agents Chemother. 2015;60:1208–1215.
   PubMed Web of Science ®Google Scholar
• Olofsson SK, Marcusson LL, Lindgren PK, Hughes D, Cars O. Selection of ciprofloxacin resistance of Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother. 2006;57:1116–1121.10.1093/jac/dkl135
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Ther. 2000;45:295–303.10.1093/jac/45.3.295
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lagace-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother. 2011;55:3169–3175.10.1128/AAC.00066-11
   PubMed Web of Science ®Google Scholar
• Marchisio M, Porto A, Joris R, Rico M, Baroni MR, Di Conza J. Susceptibility to β-lactams and quinolones of Enterobacteriaceae isolated from urinary tract infections in outpatients. Braz J Microbiol. 2015;46:1155–1159.10.1590/S1517-838246420140880
   PubMed Web of Science ®Google Scholar
• Grillon A, Schramm F, Kleinberg M, Jehl F. Comparative activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies. PLoS ONE. 2016;11(6):e0156690.10.1371/journal.pone.0156690
   PubMed Web of Science ®Google Scholar
• CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 8th ed. 2009. CLSI document M-07-08, Clinical and Laboratory Standards Institute.
   Google Scholar
• Wilson APR, Grüneberg RN. Ciprofloxacin: 10 years of clinical experience. Oxford (UK): Maxim Medical; 1997.
   Google Scholar
• Edmiston CE Jr, Suarez EC, Walker AP, Demeure MP, Frantzides CT, Schulte WJ, et al. Penetration of ciprofloxacin and fleroxacin into biliary tract. Antimicrob Agents Chemother. 1996;40:787–791.
   PubMed Web of Science ®Google Scholar
• Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, et al. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of ‘antimutant’ linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59:1014–1019.10.1128/AAC.04214-14
   PubMed Web of Science ®Google Scholar
• Firsov AA, Zinner SH. Use of modeling techniques to aid in antibiotic selection. Curr Infect Dis Rep. 2001;3:35–43.10.1007/s11908-001-0057-9
   PubMedGoogle Scholar